"Take the sale, or keep to the rules." On the materials-review floor, this binary is forced on us again and again. An aggressive claim makes the numbers in the short run, so compliance looks like a cost. Yet the conflict arises only when the time horizon is cut short. Stretch the period out, and compliance stops being something that eats into revenue and becomes the precondition for revenue to last. This piece sets out where the trade-off turns into integration, together with what makes the pharmaceutical industry peculiar.
01The Binary Vanishes When You Stretch the Time Horizon
Look only at the short run, and revenue and compliance appear to be a trade-off. Aggressive materials sell faster; trim the claims and the numbers soften. Because the profit becomes visible first, the floor experiences it as a conflict between attacking and defending. But this appearance is the consequence of cutting the time horizon short.
A violation destroys the revenue base itself, in the form of surcharges, shipment suspensions, and lost trust. In exchange for a short-term upside, you lose the foundation. Because the asymmetry runs this way — profit arrives early, the cost of a violation arrives late and large — the longer the horizon, the more keeping to the rules becomes the rational choice. The trade-off between revenue and compliance is an illusion manufactured by a short time horizon. The very structure by which aggressive claims rise up from the floor has its roots in the top-line pressure we examined in Vol. 3.
Looks like a binary
Aggressive claims sell faster and compliance reads as a cost. Because profit becomes visible first, revenue and compliance arise as a conflict.
Integration is rational
The cost of a violation arrives late and large. The longer the horizon, the more compliance is built in as the precondition for revenue to last.
The penalty is outsized
Trust is the de facto license to operate. A single scandal spreads to every product, allowing no illusion that "just this once" stays contained.
02The Price of a Violation Loads onto the Cost of Capital
Keep compliance to a matter of ethics alone, and it never reaches management. The cost of a violation can be translated into the financial language of the cost of capital. Once that is grasped, compliance can be argued not as sentiment but as a question of numbers.
Reputational damage raises the return investors demand of the company. A higher required return means a higher cost of capital, and shareholder value falls. The "ROE above the cost of capital" set out in the Itō Review presupposes that the business continues. Let a single violation cast doubt on that durability, and the premise collapses. Compliance is ethics and, at the same time, a part of managing the cost of capital. The fine may be paid once, but the raised cost of capital remains as a burden carried every year.
03In Pharma, Trust Is the De Facto License to Operate
For the same violation, the penalty in pharmaceuticals is outsized. The temptation of short-term optimization exists in every industry, but pharma carries a structure that makes it pay an especially high price.
In an industry bound up with human life, trust functions as the de facto license to operate. A scandal over one product does not stay with that product; it spreads to the trust placed in every product the company makes. This non-separability of a violation drives the penalty sharply upward. The Ministry of Health, Labour and Welfare's Report on the Monitoring Project for Sales Information Provision Activities shows that deviations recur, not confined to any single company (names anonymized). A structure that does not close at "just this once" makes pharmaceutical compliance heavier than in other industries. That is exactly why selling off trust for short-term numbers does not pay in pharma.
04Review Can Be Framed as the Precondition for Sustained Profit
With all of this in view, the words a reviewer should hand back to management come into focus. Not "compliance is the enemy of profit," but "the precondition for sustained profit." Replace a single word, and the standing of review changes.
If it is an enemy, it is a cost to be cut; if it is a precondition, it is an investment to be protected. Since a violation loads onto the cost of capital and, in pharma, spreads to every product, review can be explained as an investment that protects the revenue base. Review exists not to stop things, but to let profit continue. A reviewer who can frame review as investment rather than cost meshes with the judgments of management. The full picture of this stance is treated in Vol. 10, through the metaphor of the steering wheel rather than the brake.
- The trade-off is a short-run illusion. Stretch the time horizon, and compliance is integrated as the precondition for revenue.
- A violation damages reputation, pushes up the cost of capital, and lowers shareholder value (the Itō Review).
- In pharma, trust is the de facto license to operate. The non-separability of a violation drives the penalty of a single scandal upward across every product.
- Review is not a cost but the "precondition for sustained profit" — an investment that can be argued in the language of management.
- The Itō Review (2014, final report of a Ministry of Economy, Trade and Industry project). Argues for ROE above the cost of capital and the durability of the business; the basis for connecting compliance to managing the cost of capital.
- Tokyo Stock Exchange. Corporate Governance Code, Basic Principle 2 (appropriate cooperation with stakeholders other than shareholders). Provides that sustained corporate value rests on trust with parties beyond shareholders — employees, customers, business partners, and local communities.
- Ministry of Health, Labour and Welfare. Report on the Monitoring Project for Sales Information Provision Activities. A primary source showing that deviations in materials and information provision recur, not confined to any single company (names anonymized).
- Daiwa Bank shareholder derivative suit (Osaka District Court judgment, September 20, 2000). Showed that gaps in internal control can lead to enormous economic consequences.